Using a lozenge to target and treat oral cancer cells
Targeting OSCC cells with a lozenge to treat oral cancer
This study is testing a new, gentle lozenge made from a natural ingredient to see if it can help treat oral cancer in patients whose cancer cells have a specific protein, offering a potentially easier option than traditional treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sentrimed, INC. NIH-funded |
| Lab location | 1 site (Mullica Hill, United States) |
| Project ID | NIH-10915138 on NIH RePORTER |
What this research studies
This research investigates a new treatment for oral squamous cell carcinoma (OSCC), a type of oral cancer that is often resistant to traditional therapies. The approach involves using a nontoxic lozenge containing Maackia amurensis seed lectin (MASL), which targets a specific protein (PDPN) found on OSCC cells. The study will assess the effects of this treatment on cancer cell characteristics and immune response in patients with high PDPN expression. If successful, this could provide a less invasive option for treating oral cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with oral lesions that express high levels of PDPN and are at risk of developing OSCC.
Not a fit: Patients with oral cancers that do not express PDPN or those who have advanced-stage cancer may not benefit from this treatment.
Why it matters
Potential benefit: If successful, this research could offer a novel, less toxic treatment option for patients with oral cancer, potentially improving their quality of life.
How similar studies have performed: While targeting PDPN in oral cancer is a novel approach, similar strategies targeting specific cancer markers have shown promise in other types of cancer treatments.
Where this research is happening
Mullica Hill, United States
- Sentrimed, INC. — Mullica Hill, United States (Active)
Researchers
- Principal investigator: Goldberg, Gary — Sentrimed, INC.
- Study coordinator: Goldberg, Gary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.